Primary cutaneous centrofollicular lymphoma with a good response to radiotherapy*

Linfoma centrofolicular cutâneo primário com boa resposta a radioterapia

Cláudia Medeiros dos Santos Camargo1
Leonardo Spagnol Abraham3
Maria de Fátima Guimarães Scotelaro5
Lislaine Bomm2
Rafael Daher4
Luna Azulay Abulafia6

DOI: http://dx.doi.org/10.1590/abd1806-4841.20132427

Abstract: Primary cutaneous lymphomas have different clinical behavior and prognosis than systemic lymphomas of similar histological subtype. About 30% of non-Hodgkin lymphomas involve extranodal tissues, the skin being the second most affected body organ after the gastrointestinal tract (approximately 18%). According to the EORTC (European Organization for Research and Treatment of Cancer) classification, the lymphoma centrofollicular is indolent, since the lesions increase in size slowly over the years and spread to extracutaneous sites is uncommon. Based on this, radiotherapy has been considered the treatment of choice by many studies. We present the case of a patient who had cutaneous centrofollicular scalp lymphoma for 1 year and showed good response to radiotherapy.

Keywords: B-Lymphocytes; Lymphoma; Lymphoma, B-cell; Lymphoma, follicular; Radiotherapy

INTRODUCTION

Primary cutaneous lymphomas frequently have clinical behavior and prognosis different than systemic lymphomas of similar histological subtype. About 30% of the non-Hodgkin lymphomas affect extranodal tissues, the skin being the second most affected organ after the gastrointestinal tract, or around 18% of all lymphomas.1 According to the EORTC classification (Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer), the cutaneous centrofollicular lymphoma is a B-cell indolent lymphoma, since the lesions grow slowly in size over the years and dissemination to extracutaneous sites is uncommon.2 With that in mind, radiotherapy has been referred as the first-choice treatment by many studies.3,4 The case of a patient with cutaneous centrofollicular lymphoma on the scalp with one year of evolution is presented, which showed good response to radiotherapy.

CASE REPORT

Received on 09.01.2013.
Approved by the Advisory Board and accepted for publication on 29.01.2013.
Conflict of interest: None
Financial funding: None

1 MD - Graduate student in Dermatology at Hospital Universitário Pedro Ernesto – Universidade do Estado do Rio de Janeiro (HUPE-UERJ) – Rio de Janeiro (RJ), Brazil.
2 Dermatologist – Private Clinic – Rio de Janeiro (RJ), Brazil.
3 MD, Master's Degree program student – Volunteer dermatologist at Hospital Universitário de Brasília – Universidade de Brasília (HUB-UnB) – Brasília (DF), Brazil.
4 MD, Radiotherapist in charge of the Radiotherapy Service at Hospital Universitário Pedro Ernesto – Universidade do Estado do Rio de Janeiro (HUPE-UERJ) – Rio de Janeiro (RJ), Brazil.
5 MD, PhD – Professor at the Dermatopathology Department of Hospital Universitário Pedro Ernesto – Universidade do Estado do Rio de Janeiro (HUPE-UERJ) – Rio de Janeiro (RJ), Brazil.
6 MD, PhD – Professor at the Dermatology Department of Hospital Universitário Pedro Ernesto – Universidade do Estado do Rio de Janeiro (HUPE-UERJ) – Rio de Janeiro (RJ), Brazil.

©2013 by Anais Brasileiros de Dermatologia

An Bras Dermatol. 2013;88(6 Suppl 1):136-8.
CASE REPORT

A 45 year-old white male, previously healthy, presented infiltrated plaques and coalescent nodules on the left parietal region one year ago. He reported history of local trauma six months before the onset of the lesion. He denied local or systemic symptomatology (fever, night sweat or weight loss). On the dermatological exam were found plaques and erythematous nodules of hard consistency, measuring about 8x4 cm (Figure 1). Palpable lymphadenopathy was absent. The histopathological exam demonstrated a large diffuse dermal infiltrate that spared the epidermis, with a partial follicular component (Figure 2). The infiltrate was composed of a population of central follicle cells, predominantly with multilobed nuclei, associated with large centroblasts and mixed centrocytes and surrounded by a great quantity of small reactive T lymphocytes (Figures 3 and 4).

Immunohistochemistry was positive for CD5 and CD20 and negative for CD30. After the centrofollicular lymphoma diagnosis, the patient was referred for hematologic evaluation for research on systemic disease, which was negative; the classification was TNM TxN0M0. He was submitted to radiotherapy with 3,060 cGy in 17 fractions on the scalp lesion, with the 9 MeV direct electronic fields technique for 25 days, with good local response.

DISCUSSION

The cutaneous B-cell lymphomas represent 25% of cutaneous lymphomas. By the new WHO-EORTC classification, these are divided into primary cutaneous centrofollicular lymphoma, primary cutaneous marginal zone lymphoma and primary cutaneous large cell lymphoma leg type. The primary cutaneous
Primary cutaneous lymphoma centrofolicular with a good response to radiotherapy. Camargo CMS, Bomm L, Abraham LS, Daher R, Scotelaro MFG, Azulay Abulafia L.

How to cite this article: Camargo CMS, Bomm L, Abraham LS, Daher R, Scotelaro MFGA, Azulay Abulafia L. Primary cutaneous lymphoma centrofolicular with a good response to radiotherapy. An Bras Dermatol. 2013;88(6 Suppl 1):S136-8.

REFERENCES
1. Moricz CZ, Sanches JR. Processos linfoproliferativos da pele. Parte -1 Linfomas cutâneos de células B. An Bras Dermatol. 2005;80:461-71.
2. Serif NJ, Noordijk EM, Kim YH, Bagot M, Berti E, Cerroni L, et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood. 2008;112:1600-9.
3. Smith BD, Glusac EJ, McNiff JM, Smith GL, Heald PW, Cooper DL, et al. Primary Cutaneous B-Cell Lymphoma Treated With Radiotherapy: A Comparison of the European Organization for Research and Treatment of Cancer and the WHO Classification Systems. J Clin Oncol. 2004;22:634-9.
4. Pandolfino TL, Siegel RS, Kuzel TM, Guitart J. Primary cutaneous B-cell lymphoma: Review and current concepts. J Clin Oncol. 2000;18:2152-68.
5. Bergman R. Pseudolymphoma and cutaneous lymphoma: facts and controversies. Clin Dermatol. 2010;28:568-74.
6. Kirova YM, Piedbois Y, Le Bourgeois JP. Radiotherapy in the management of cutaneous B-cell lymphoma: Our experience in 25 cases. Radiother Oncol. 1999;52:15-8.
7. Halperin EC, Perez CA, Brady LW, Wazer DE, Freeman C, Prosznitz LR. Principles and Practice of Radiation Oncology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p.1748-76.

Centrofollicular lymphoma is a relatively common lymphoma, characterized by the neoplastic proliferation of centrocytes and centroblasts confined to the skin. The survival rate for this kind of lymphoma is 95% in 5 years, its prognosis being very favorable with low probability of extracutaneous dissemination. Clinically, they present as plaques or nodes, solitary or grouped, being either normochromic or erythematous. Their favorite sites are the head (front and scalp) and dorsum. Recurrences are observed in about 50% of the cases, but dissemination to internal organs is rare. The histological exam is characterized by a pattern of diffuse and/or follicular growth findings, composed of a variable mix of small and/or big neoplastic cleaved cells (centroblasts), aside from immunoblasts, small lymphocytes, histiocytes, eosinophils and plasma cells. Sometimes there may be reactive lymphoid follicles resembling germinal centers, which, many times, hinders the differential diagnosis with pseudo lymphomas. The immunohistochemistry of tumor cells reveals CD20, CD79a, CD10 and bcl-6 neoplastic cells masked as positive. Markers for CD5, CD43 and bcl-2 are rarely positive. Since the cutaneous metastases of nodal follicular lymphoma strongly express bcl-2 and CD10 proteins, the differential diagnosis can be done between these and the primary cutaneous lymphomas. Lymphomas are neoplasms that are very sensitive to ionizing radiation. Lymphoma sensitivity is usually greater than that of the local surrounding tissue, which makes them very different from other solid neoplasms. There is little data about the dose-response of radiotherapy for non-Hodgkin lymphomas. Studies demonstrate that for the cutaneous centrofollicular lymphoma radiotherapy is the first-line treatment of choice. The 25-35Gy dose is able to control the disease more than 90%, the radiation field being a little larger than the tumor so that non-visible lesions are also treated. Other treatments indicated are surgical excision of small lesions; for too extensive cutaneous lesions and extracutaneous disease, chemotherapy is indicated. The therapeutic efficiency of anti-CD20 antibody, intralesional or systemic, has recently been demonstrated. Our patient presented excellent response to radiotherapy, with complete resolution of the cutaneous lesion, presenting only an alopecia plaque on the lesion’s site (Figure 5).

![FIGURE 5: Complete resolution of cutaneous lesion, presenting only cicatricial alopecia plaque on the site](image-url)